-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$12.85439.92% Upside
Recent Analyst Forecasts and Stock Ratings
Editas Medicine, Inc. Frequently Asked Questions
-
What analysts cover Editas Medicine, Inc.?
Editas Medicine, Inc. has been rated by research analysts at Barclays, Wells Fargo, Robert W. Baird, Truist Financial, Bank of America Securities, Evercore ISI in the past 90 days.